-
Surfshark Adds Real-Time Call Protection to iOS App in Version 5.3.0
-
Samsung Galaxy Buds Active Leak Reveals ANC, Ear-Hook Design and One UI 9.5 Integration
-
Saudi PIF Retains Top Sovereign Wealth Fund Brand Title for Third Year
-
Egypt and Syria Sign Agreement to Restore Direct Flights After 14-Year Hiatus
-
Professor Shahida Moosa Pioneers Medical Genomics in South Africa Amid Testing Shortages
-
Van Gogh’s ‘Châtaigniers en Fleurs’ Sets $285m Record at Sotheby’s
-
Texas Marijuana Decriminalization Faces Uncertain Future Under New Attorney General
-
Anthropic Sets Record $81.3 Billion IPO Valuing AI Firm at $1.5 Trillion
-
Early Black Friday Laptop Deals: MacBook Neo, IdeaPad Slim 5x, and Surface Laptop Prices Drop
-
eThekwini Faces R6.5bn Flood Claim from Toyota’s Insurer
-
2026 East Bay Nosh Awards Voting Opens for Food and Drink Favorites
-
Jerash Holdings Partners with International Finance Corporation (IFC) to Pursue EDGE Gender Certification
-
Arrive AI Eliminates All Debt Through Preferred Equity Exchange
-
QNX Brings Physical AI and Next-Generation Software-Defined Vehicle Innovation to CES 2027
-
More Than Half of Teen AI Chatbot Users Use Them Daily, and 46% Say It Feels Like Talking to a Human, New Family Online Safety Institute Research Finds
-
multiQure Begins Manufacturing Phase of MQ-201 Gene Therapy for First Huntington's Disease Patients - U.S.-Based Andelyn Biosciences Selected as Manufacturing Partner
-
MicroVision and Blue-Band to Support $3 Million Federally Funded Intelligent Transportation Initiative in Louisville, Kentucky
-
The 2026 MDaudit Annual Benchmark Report Spotlights AI's Impact on Financial Risk as Payer Denials and Audits Continue an Upward Trajectory
-
Metano Emerges From Stealth to Unify AI Agent Security Across the Enterprise
-
Lumber's Union CBA Agent Launches in Sage Agent Marketplace to Help Simplify Union Payroll Compliance
-
ATWEC Technologies, Inc. (OTCID: ATWT) Engages Michael Gillespie & Associates, PLLC to Audit Fiscal 2026 and 2025 Consolidated Financial Statements and Changes Fiscal Year End to October 31
-
Vogenx Set to Join the Russell 2000(R), Russell 3000(R), and Russell Microcap(R) Indexes
-
Stemtech Corporation Partners with Fitness Icon Tony Little to Launch Stemtech Biosciences Digital Campaign
-
Go Green Global Technologies Corp. Appoints Dennis Beckert as Interim Chief Executive Officer
-
InstaLILY Launches Lily for Sales on Microsoft Dynamics 365, Where Sellers and AI Agents Work Together in Shared Rooms
-
Wave AI, the AI Note Taker for In-Person Meetings, Passes 5 Million Recorded Hours
-
Increasing Electrification Raises Grid Risk and Cost Pressure for Industrial Sites, ABI Research Finds
-
After 20 Years of Modernizing Other Companies' Software, Polcode Turns the Lens on Itself
-
NoHo, Inc. Acquires Four Placer Gold Claims in Clark County, Nevada from Gold Stake Mining Inc.
-
Making the Most of a Long Weekend Without Leaving Town
-
Bob's Watches Founder Paul Altieri Unveils Private Collection of Vintage Rolex Watches in New Book, "NOT FOR SALE"
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 19
-
Hemogenyx Pharmaceuticals PLC - Chairman Receives Prestigious Award
-
American Critical Minerals Reports High Grade Potash Intersection of 6.55m Grading 38.51 wt.% KCl at its Green River Project, Utah
-
LASE to Premiere Quantum Bullet(TM) at Counter UAS Technology Conference in Washington, D.C.
-
First Canadian Graphite Reports 43.9% Graphitic Carbon Sample and Encouraging Coarse-Flake Characteristics at Zone 13 at Lac Guéret South
-
IRS Shuts Down FIRE Today: What Information Return Filers Need to Know Before the 2027 Filing Season
-
Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout
-
Trustpoint Xposure Completes More Than 200 AI Visibility Audits Across Professional Services
-
Gamma Resources Announces Expansion of Mesa Arc Uranium Project in New Mexico to 4,760 Acres, Completes Radon Flux Baseline Survey
-
Golden Minerals Completes Drilling Desierto, Argentina
-
Guanajuato Silver Reports Q3 Operating and Financial Results
-
Helio Corporation Engages CORE IR to Provide Investor Relations, Capital Markets Advisory and Media Relations Services
-
Greene Concepts Connects Consumer Needs with Manufacturing Strategy
-
Karbon-X (OTCQB:KARX) Enters California's Multi-Billion-Dollar Compliance Carbon Market Following CITSS Approval
-
Skilled Nursing Facilities Face 2027 Revenue Cycle Reckoning as Payer Burdens Reshape Admissions and Outsourcing
-
Who Is the Best MTF Top Surgeon?
-
APPA Launches 2026 Pet Industry Holiday Gift Guide, Backed by New Pet Gifting Data
-
United Bancorp, Inc. Increases its Fourth Quarter Cash Dividend Payment to $0.20 per Share, which Produces a Forward Yield of 5.4%
-
moveBuddha Doubles Moving Company Database to More Than 9,000 U.S. Movers
Medicure Reports Financial Results for Quarter Ended September 30, 2026 and Schedules November 23, 2026 Conference Call
WINNIPEG, MB / ACCESS Newswire / November 19, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC Pink:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended September 30, 2026 and will have a conference call to present the Financial Results on November 23, 2026 at 8:30 am Eastern Time.
Quarter Ended September 30, 2026 Highlights:
- Recorded total net revenue of $7.9 million during the period ended September 30, 2026, compared to $8.2 million for the period ended September 30, 2025;
- Recorded total net revenue from the sale of ZYPITAMAG®of $1.7 million ($781,000 through the traditional insured channels, and $930,000 through Marley Drug) during the quarter ended September 30, 2026, compared to $1.7 million ($769,000 through the traditional insured channels, and $917,000 through Marley Drug) for the quarter ended September 30, 2025;
- Recorded total net revenue from the sale of AGGRASTAT® of $979,000 during the quarter ended September 30, 2026, compared to $1.0 million during the quarter ended September 30, 2025;
- The Pharmacy Business Segment, which includes Marley Drug, and the Company's two 2025 acquired pharmacies, Gateway Medical Pharmacy and West Olympia Pharmacy, recorded total net revenue of $6.1 million ($930,000 from sales of ZYPITAMAG®, and $5.2 million from other pharmacy revenue) during the quarter ended September 30, 2026, compared to net revenue of $6.4 million ($917,000 from sales of ZYPITAMAG®, and $5.4 million from other pharmacy revenue) during the quarter ended September 30, 2025;
- Medicure invested $676,000 in research and development during the quarter ended September 30, 2026, underscoring our commitment to advancing innovative therapies, such as the Phase 3 trial of the Company's investigational product MC-1 for the treatment of PNPO deficiency and delivering long-term value to patients and shareholders;
- Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA1) for the quarter ended September 30, 2026 was negative $820,000, compared to negative adjusted EBITDA of $597,000 for the quarter ended September 30, 2025 and;
- Net loss for the quarter ended September 30, 2026 was $1.3 million or $0.13 per share, compared to a net loss of $1.4 million or $0.13 per share for the quarter ended September 30, 2025; the net loss includes non-cash expenses of $669,000 relating to amortization of the assets relating to the purchase of ZYPITAMAG® and the Pharmacy Business Segment.
Financial Results
Marley Drug recorded net revenue of $3.5 million during the quarter ended September 30, 2026 compared to net revenue of $3.3 million during the quarter ended September 30, 2025.The pharmacy business continues to focus on diversifying its revenue by securing exclusive product offerings and partnerships. Going forward, the focus of Marley Drug is to continue growing its sales of ZYPITAMAG® and increasing its exclusive product offerings and business partnerships.
West Olympia Pharmacy and Gateway Pharmacy, both acquired in the first half of 2025, contributed net revenue of $2.0 million and $739,000, respectively, during the quarter ended September 30, 2026, compared to $2.2 million and $890,000 of revenue, respectively, for the quarter ended September 30, 2025.
ZYPITAMAG through insured channels contributed $781,000 of revenue for the quarter ended September 30, 2026, consistent with $769,000 for the quarter ended September 30, 2025. The slight increase in ZYPITAMAG® revenue during the period ended September 30, 2026, can be attributed to higher utilization of the product through insurance formularies. This amount does not include sales of ZYPITAMAG® through the Pharmacy Business Segment.
Net AGGRASTAT® product sales for the quarter ended September 30, 2026 were $979,000, compared to $1.0 million during the quarter ended September 30, 2025. The slight decrease in AGGRASTAT® revenues compared to the same period in the prior year is the result of a decrease in the volume of AGGRASTAT® sold and pricing competition from generic tirofiban.
Research and development expenditures for the quarter ended September 30, 2026 totaled $676,000 compared to $717,000 for the quarter ended September 30, 2025. Research and development expenditures include costs associated with the Company's on-going clinical development and pre-clinical programs including salaries and monitoring costs, as well as research and development costs associated with the development projects being undertaken to develop additional products.
Adjusted EBITDA for the quarter ended September 30, 2026 was negative $820,000 compared to adjusted EBITDA of negative $597,000 for the quarter ended September 30, 2025. The main factors contributing to the decrease in adjusted EBITDA during the current period are an increase in cost of goods sold, after adding back the recovery of previously written down inventory.
Net loss for the quarter ended September 30, 2026 was $1.3 million or $0.13 per share, consistent with a net loss of $1.4 million or $0.13 per share for the quarter ended September 30, 2025.
At September 30, 2026, the Company had unrestricted cash totaling $1.1 million, a decrease from the $3.8 million of unrestricted cash held as of December 31, 2025. The decrease in cash during the current period is primarily due to changes in working capital as a result of a decrease in accounts payable.
All amounts referenced herein are in Canadian dollars unless otherwise noted.
The full financial statements are available at www.sedarplus.ca and on the Company's website at www.medicure.com.
Notes
- The Company defines EBITDA as "earnings before interest, taxes, depreciation, amortization and other income or expense" and Adjusted EBITDA as "EBITDA adjusted for non‑cash and non-recurring items". The terms "EBITDA" and "Adjusted EBITDA", as it relates to the three month period ended September 30, 2026 and 2025 results prepared using IFRS, do not have any standardized meaning according to IFRS. It is therefore unlikely to be comparable to similar measures presented by other companies.
Conference Call Info:
Topic: Medicure's Financial Results for the Quarter Ended September 30, 2026
Call date: Monday, November 23, 2026
Time: 8:30 AM Eastern Time (8:30 AM Manitoba Time)
Toll Free: 1 (877) 545-0320
International: 1 (973) 528-0002
Participant Access Code: 476389
Webcast: This conference call will be webcast live over the internet at the following link: https://www.webcaster5.com/Webcast/Page/2965/54875
About Medicure Inc.
Medicure is a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug Inc. ("Marley Drug"), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug® is committed to improving access to medications for all Americans together with exceptional customer service and free home delivery. Medicure also operates Gateway Medical Pharmacy, located in Portland, Oregon in a medical office building near major transportation lines and multiple healthcare clinics and centers. In addition to regular customers, the pharmacy services multiple long-term care facilities and provides non-sterile compounding services. Medicure also operates West Olympia Pharmacy, located in Olympia, Washington in a medical office complex near multiple clinics. For more information visit www.marleydrug.com. For more information about Medicure please visit www.medicure.com. For additional information about AGGRASTAT®, please visit www.aggrastat.com or refer to the full Prescribing Information. For additional information about ZYPITAMAG®, please visit www.zypitamag.com or refer to the full Prescribing Information.
To be added to Medicure's e-mail list, please visit:
http://medicure.mediaroom.com/alerts
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Information: Statements contained in this press release that are not statements of historical fact, including, without limitation, statements containing the words "believes", "may", "plans", "will", "estimates", "continues", "anticipates", "intends", "expects" and similar expressions, may constitute "forward-looking information" within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referred to as "forward-looking statements"). Forward-looking statements, include estimates, analysis and opinions of management of the Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factors beyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers are cautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others, the Company's future product revenues, expected results, including future revenue from P5P, the likelihood of receiving a priority review voucher from the United State Food and Drug Administration, expected future growth in revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approval to market the Company's products, the ability to protect its intellectual property, dependence upon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological change in the industry. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions about: general business and economic conditions; the impact of changes in Canadian-US dollar and other foreign exchange rates on the Company's revenues, costs and results; the timing of the receipt of regulatory and governmental approvals for the Company's research and development projects; the availability of financing for the Company's commercial operations and/or research and development projects, or the availability of financing on reasonable terms; results of current and future clinical trials; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing list of important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additional discussion regarding the risks and uncertainties relating to the Company and its business can be found in the Company's other filings with the applicable Canadian securities regulatory authorities or the US Securities and Exchange Commission, and in the "Risk Factors" section of its current Form 20F.
AGGRASTAT® (tirofiban hydrochloride) injection, ZYPITAMAG® (pitavastatin) tablets, and Marley Drug® are registered trademarks.
For more information, please contact:
Dr. Albert D. Friesen
Chief Executive Officer
Tel. 888-435-2220
Fax 204-488-9823
E-mail: [email protected]
www.medicure.com
Condensed Consolidated Interim Statements of Financial Position
(expressed in thousands of Canadian dollars, except per share amounts)
(unaudited)
| September 30, 2026 | December 31, 2025 | |||
Assets | ||||
Current assets: | ||||
Cash and cash equivalents | $ | 1,077 | $ | 3,835 |
Accounts receivable | 5,152 | 4,817 | ||
Inventories | 2,805 | 2,942 | ||
Prepaid expenses | 215 | 293 | ||
Total current assets | 9,249 | 11,887 | ||
Non-current assets: | ||||
Property and equipment | 897 | 945 | ||
Intangible assets | 6,340 | 7,748 | ||
Goodwill | 4,410 | 4,260 | ||
Other assets | 112 | 109 | ||
Total non-current assets | 11,759 | 13,062 | ||
Total assets | $ | 21,008 | $ | 24,949 |
Liabilities and Equity | ||||
Current liabilities: | ||||
Accounts payable and accrued liabilities | $ | 9,959 | $ | 10,587 |
Income taxes payable | 6 | 90 | ||
Current portion of lease obligations | 437 | 464 | ||
Acquisition payable | - | 388 | ||
Holdback payable | - | 84 | ||
Total current liabilities | 10,402 | 11,613 | ||
Non-current liabilities | ||||
Lease obligations | 411 | 427 | ||
Total non-current liabilities | 411 | 427 | ||
Total liabilities | 10,813 | 12,040 | ||
Equity: | ||||
Share capital | 81,014 | 81,014 | ||
Contributed surplus | 11,048 | 11,055 | ||
Accumulated other comprehensive loss | (4,722 | ) | (5,172 | ) |
Deficit | (77,145 | ) | (73,988 | ) |
Total equity | 10,195 | 12,909 | ||
Total liabilities and equity | $ | 21,008 | $ | 24,949 |
Condensed Consolidated Interim Statements of Net Loss and Comprehensive Loss
(expressed in thousands of Canadian dollars, except per share amounts)
(unaudited)
| For the three months ended September 30 | For the nine months ended September 30 | |||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||
Revenue, net | $ | 7,906 | $ | 8,159 | $ | 23,280 | $ | 20,312 | ||||
Cost of goods sold | 5,326 | 5,386 | 13,981 | 11,261 | ||||||||
Gross profit | 2,580 | 2,773 | 9,299 | 9,051 | ||||||||
Expenses | ||||||||||||
Selling | 2,137 | 2,199 | 6,848 | 6,161 | ||||||||
General and administrative | 1,038 | 1,167 | 3,303 | 3,526 | ||||||||
Research and development | 676 | 717 | 2,139 | 2,028 | ||||||||
| 3,851 | 4,083 | 12,290 | 11,715 | |||||||||
Finance costs (income): | ||||||||||||
Finance expense (income), net | 15 | 2 | 44 | (52 | ) | |||||||
Foreign exchange loss, net | 29 | 21 | 56 | 105 | ||||||||
| 44 | 23 | 100 | 53 | |||||||||
Net loss before income taxes | $ | (1,315 | ) | $ | (1,333 | ) | $ | (3,091 | ) | $ | (2,717 | ) |
Income tax expense | ||||||||||||
Current | 8 | 63 | 66 | 159 | ||||||||
Net loss | $ | (1,323 | ) | $ | (1,396 | ) | $ | (3,157 | ) | $ | (2,876 | ) |
Other comprehensive income: | ||||||||||||
Item that may be reclassified to profit or loss | ||||||||||||
Exchange differences on translation of foreign subsidiaries | (51 | ) | 362 | 450 | (695 | ) | ||||||
Other comprehensive income (loss), net of tax | (51 | ) | 362 | 450 | (695 | ) | ||||||
Comprehensive loss | $ | (1,374 | ) | $ | (1,034 | ) | $ | (2,707 | ) | $ | (3,571 | ) |
Loss per share | ||||||||||||
Basic | $ | (0.13 | ) | $ | (0.13 | ) | $ | (0.30 | ) | $ | (0.28 | ) |
Diluted | $ | (0.13 | ) | $ | (0.13 | ) | $ | (0.30 | ) | $ | (0.28 | ) |
Condensed Consolidated Interim Statements of Cash Flows
(expressed in thousands of Canadian dollars, except per share amounts)
(unaudited)
For the nine months ended September 30 | 2026 | 2025 | ||||
Cash (used in) provided by: | ||||||
Operating activities: | ||||||
Net loss for the period | $ | (3,157 | ) | $ | (2,876 | ) |
Adjustments for: | ||||||
Amortization of property, plant and equipment | 338 | 373 | ||||
Amortization of intangible assets | 1,640 | 1,594 | ||||
Share-based compensation | (7 | ) | 101 | |||
Inventory recovery, net | (212 | ) | - | |||
Finance expense (income), net | 44 | (52 | ) | |||
Unrealized foreign exchange loss | 56 | 105 | ||||
Income tax expense | 66 | 159 | ||||
Change in the following: | ||||||
Accounts receivable | (244 | ) | 819 | |||
Inventories | 434 | (524 | ) | |||
Prepaid expenses | 83 | (128 | ) | |||
Accounts payable and accrued liabilities | (963 | ) | (28 | ) | ||
Interest (paid) received, net | (4 | ) | 109 | |||
Income taxes paid | (150 | ) | (244 | ) | ||
Cash used in operating activities | (2,076 | ) | (592 | ) | ||
Investing activities: | ||||||
Acquisition of Gateway Pharmacy | (388 | ) | (542 | ) | ||
Acquisition of West Olympia Pharmacy | - | (1,635 | ) | |||
Cash flows used in investing activities | (388 | ) | (2,177 | ) | ||
Financing activities: | ||||||
Lease payments | (324 | ) | (304 | ) | ||
Cash flows used in financing activities | (324 | ) | (304 | ) | ||
Foreign exchange gain on cash held in foreign currency | 30 | - | ||||
Decrease in cash and cash equivalents | (2,758 | ) | (3,073 | ) | ||
Cash and cash equivalents, beginning of period | 3,835 | 7,191 | ||||
Cash and cash equivalents, end of period | $ | 1,077 | $ | 4,118 | ||
SOURCE: Medicure, Inc.
View the original press release on ACCESS Newswire
Y.Kobayashi--AMWN